Preparation and imaging of rhenium-188 labeled human serum albumin microsphere in orthotopic hepatoma rats.
OBJECTIVE
The present study relates to a method for preparing 188Re-labeled human serum albumin microspheres (HSAM) by 188Re(I)-tricarbonyl ion(188Re(OH2)3(CO)3)+). This radioactive particle can be subjected to radioembolization for liver tumor.


METHODS
The particle sizes and conformations of HSA microspheres were analyzed by Particle sizes-Malvern mastersizer and Scanning Electron Microscope (SEM). For preparing 188Re(I)-tricarbonyl ion, the 188ReO4- was eluted from a 188W/188Re generator with saline. The radio labeling efficiency was analyzed with high-performance liquid chromatography (HPLC). Amino borane-reduced 188ReO4-was interacted with carbon oxide to form (188Re(OH2)3(CO)3]+). For preparing 188Re-HSA microspheres, the 188Re(I)-tricarbonyl ion was added into a vial with HSA microspheres. The in vitro stability was investigated. The rat was injected with 188Re-HSA microspheres via hepatic artery route. Nano-SPECT/CT Imaging was acquired after injection of 188Re-HSA microspheres.


RESULTS
The shape of HSA microsphere was rough surfaced sphere or oval-shaped. The particle size was distributed between 20 and 35μm. In the RP-HPLC-UV chromatography, the yield of 188Re(I)-tricarbonyl ion was 75-80%. The labeling efficiency of 188Re-HSA microspheres in this method was more than 85%. After incubation, the 188Re(I)-tricarbonyl ion labeled HSA microspheres were found to be stable in vitro in normal saline and rat plasma. The result of Nano-SPECT/CT Imaging quantification analysis indicated that the percentage of injection dose %ID was maintained at 95% ID-88% ID from 2 to 72h after injection with 188Re- HSA microspheres.


CONCLUSIONS
The method of 188Re(I)-tricarbonyl ion labeled HSA microspheres can proceed with high labeling yield. Furthermore, this method provided a convenient method for radio-labeling of HSA microspheres with 188Re as well as a kit for manufacturing.
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Hsiao-Chiang
HC
Ni
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Chia-Yu
CY
Yu
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Su-Jung
SJ
Chen
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Liang-Cheng
LC
Chen
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Chien-Hong
CH
Lin
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Wan-Chi
WC
Lee
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Cheng-Hui
CH
Chuang
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Chung-Li
CL
Ho
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
Chih-Hsien
CH
Chang
Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC. Electronic address: twlee@iner.gov.tw.
Te-Wei
TW
Lee
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D003287:Contrast Media; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000532:radiotherapy*; D008297:Male; D008863:Microspheres; D011868:Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012211:Rhenium / Q000627:therapeutic use*; D012709:Serum Albumin / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D003287:Contrast Media; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012709:Serum Albumin; D012211:Rhenium
188Re(I)-tricarbonyl ion; Human serum albumin microspheres